Drug General Information (ID: DDIB983T4I)
Drug Name			Bivalirudin		Drug Info		Oxaprozin		Drug Info
Drug Type		Small molecule				Small molecule
Therapeutic Class		Antithrombotic Agents				Antiinflammatory Agents
Structure

Mechanism of Bivalirudin-Oxaprozin Interaction (Severity Level: Moderate)
Increased risk of bleeding Click to Show/Hide Mechanism Graph
Drug Name		Bivalirudin				Oxaprozin
Mechanism		Risk of bleeding Anticoagulant				Risk of bleeding Antiplatelet effects
Key Mechanism Factor 1
		Factor Name		Bleeding
		Factor Description		Patients may be at risk for bleeding when the outcome of a disease or disease treatment confounds the standard mechanisms for maintaining hemostasis. Signs or symptoms of abnormal bleeding include: bleeding that takes a long time to stop (including nosebleeds, bleeding gums, bleeding from cuts and abrasions, and menstrual bleeding); severe unexplained bruising, or bruising that becomes larger; blood in the urine or stool, etc.
Mechanism Description		Increased risk of bleeding by the combination of Bivalirudin and Oxaprozin

Recommended Action
Management		Until further data are available, the coadministration of bivalirudin and antiplatelet agents, and possibly other agents with antiplatelet activity such as nonsteroidal anti-inflammatory drugs (NSAIDs), should probably be undertaken with caution. Close clinical and laboratory observation for bleeding complications is recommended.

References
1	Product Information. Angiomax (bivalirudin) The Medicines Compny, Cambridge, MA.